Is moderate amounts of nicotine good or bad if taken orally like in a lozenge?

The short version: oral nicotine is net harmful at any dose that produces a biological effect, and the evidence for benefit only exists in the specific context of harm reduction for people already addicted to burning tobacco.

The evidence for oral nicotine’s harms is stronger and older than the evidence for its benefits. A 1986 study in monkeys found that chronic oral nicotine at roughly 6 mg/kg/day pushed blood lipids toward an atherogenic profile: higher LDL and total cholesterol, a lower HDL ratio [6]. That is a direct vascular harm from nicotine itself, not from smoke. For a non-smoker starting a lozenge, that means a measurable cardiovascular cost for zero baseline risk.

The claimed benefit is smoking cessation, and the evidence here is thin. A 2010 study of nicotine lozenges plus behavioral intervention measured only cotinine and toxicant reduction in people still using smokeless tobacco, not quit rates [1]. A 2001 survey of English adults found that the people using nicotine replacement therapy were less likely to have quit than those who used willpower alone: 190 current smokers had used gum versus only 49 ex-smokers [9]. That is not evidence of efficacy. It is evidence that the people who struggle most are the ones who buy the product.

The acute harms are documented. In a 2022 pharmacokinetic study, the nicotine lozenge produced the highest rate of product-emergent adverse events among three NRT products: 13 events attributed to the lozenge versus 9 for gum and 7 for a nicotine pouch [2]. The most common effects were nausea, dizziness, and throat irritation. The lozenge also scored lowest on subjective measures: 24 out of 32 participants rated the lozenge below 45 on a 100-point liking scale [2]. People found it unpleasant, and the safety profile is dominated by cholinergic side effects from its mechanism.

The mechanistic picture is even worse for a non-smoker. Oral nicotine raises heart rate and blood pressure acutely: the gum in the 1988 study raised HR by 13.6 bpm and systolic BP by 16 mm Hg [7]. The pharmacokinetic profile of the lozenge shows bioavailability equivalent to a 4 mg nicotine pouch, with a Tmax around one hour and a half-life of 2.7 hours [4, 2]. That means sustained cardiovascular load throughout the day. Over weeks or months, the colloid-level effect matters: nicotine is a vasoconstrictor that impairs microvascular flow, and the lipid data from the primate study suggests it directly destabilizes blood chemistry [6].

The evidence never compares a nicotone-naive person taking a lozenge against a true placebo over years. The gap is not an oversight. The question of "moderate amounts of nicotine for a healthy non-smoker" was never studied, because the product was never designed for that person. The only population where oral nicotine shows any net benefit is the addicted smoker substituting a cleaner delivery system, and even there the cessation evidence is weak.

My call: for a non-smoker, moderate oral nicotine produces documented cardiovascular and lipid harms with zero offsetting benefit.